CP promoted the β-TrCP-dependent degradation of Nrf2 in a glucocorticoid receptor-dependent manner, and when combined with Rapamycin treatment, CP strongly inhibited the growth of Keap1-mutated tumor cells [187] (Table 2). The gene discussed is KEAP1; the disease is neoplasm.